+7.7%
AAL vs MRNA
+945.0%
-937.3%
-37.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.3% | +13.1% | -6.8% | +6.1% |
| 7D | +8.3% | +20.6% | -12.3% | +8.0% |
| 30D | +6.2% | +27.1% | -20.9% | +5.8% |
| 3M | -17.7% | +353.4% | -371.1% | -21.0% |
| 6M | +15.4% | +446.3% | -430.8% | +6.6% |
| YTD | -11.1% | +776.2% | -787.3% | -21.5% |
| 1Y | +7.7% | +987.9% | -980.2% | -8.8% |
| All | +7.7% | +945.0% | -937.3% | -8.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling